Pfizer inks strategic collaboration with Syapse to analyze RWD, advance outcomes research

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/utah778)
(Image: Getty/utah778)

Related tags: Pfizer, Syapse, Real-world data, Real-world evidence, Outcomes research, Oncology

Syapse today announces a strategic collaboration with Pfizer through which it will generate insights from de-identified real-world data and advance oncology outcomes research.

Syapse’s insights platform, data sharing network, and industry partnerships help advance the delivery of precision cancer care, according to the company, which today announced a strategic collaboration with Pfizer.

“With its health system partners, Syapse has built a network of real-world data that offers a unique view of modern cancer care, including how molecular tests are used to diagnose and treat patients. A real-world database, if you will,”​ a Syapse spokesperson told us.

The company’s partners include Advocate Aurora Health, CommonSpirit Health, Henry Ford Health System, Providence St. Joseph Health, and Seoul National University Hospital. Syapse also earlier this year announced a collaboration with Amgen​, and in 2018 initiated a partnership with Medidata​ to develop a new suite of solutions addressing precision medicine challenges.

Per its strategic collaboration with Pfizer, the companies will initially focus on molecular testing and precision oncology therapy choices and outcomes of patients in the US health care system.

“Syapse will provide Pfizer with the ability to analyze this de-identified real-world data and work with them to collaboratively advance outcomes research projects,”​ the spokesperson added.

The deal with Syapse is Pfizer's latest through which the pharma company aims to advance oncology through the use of real-world data. Pfizer in April of this year announced a partnership with Concerto HealthAI​ to accelerate actionable insights for Pfizer’s precision oncology work on investigational and commercialized therapeutics for the treatment of solid tumors and hematologic malignancies.

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Related suppliers

Follow us

Products

View more

Webinars